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Abstract
Background: Subacromial disorders are considered to be one of the most common pathologies affecting the
shoulder. Optimal therapy for shoulder pain (SP) in primary care is yet unknown, since clinical history and physical
examination do not provide decisive evidence as to the patho-anatomical origin of the symptoms. Optimal
decision strategies can be furthered by applying ultrasound imaging (US), an accurate method in diagnosing SP,
demonstrating a clear relationship between diagnosis and available therapies. Yet, the clinical cost-effectiveness of
applying US in the management of SP in primary care has not been studied. The aim of this paper is to describe
the design and methods of a trial assessing the cost-effectiveness of ultrasound imaging as a diagnostic triage tool
to improve management of primary care patients with non-chronic shoulder pain.
Methods/Design: This randomised controlled trial (RCT) will involve 226 adult patients with suspected subacromial
disorders recruited by general practitioners. During a Qualification period of two weeks, patients receive care as
usual as advised by the Dutch College of General Practitioners, and patients are referred for US. Patients with
insufficient improvement qualify for the RCT. These patients are then randomly assigned to the intervention or the
control group. The therapies used in both groups are the same (corticosteroid injections, referral to a
physiotherapist or orthopedic surgeon) except that therapies used in the intervention group will be tailored based
on the US results. Ultrasound diagnosed disorders include tendinopathy, calcific tendinitis, partial and full thickness
tears, and subacromial bursitis. The primary outcome is patient-perceived recovery at 52 weeks, using the Global
Perceived Effect questionnaire. Secondary outcomes are disease specific and generic quality of life, cost-
effectiveness, and the adherence to the initial applied treatment. Outcome measures will be assessed at baseline,
13, 26, 39 and 52 weeks after inclusion. An economic evaluation will be performed from both a health care and
societal perspective with a time horizon of 52 weeks.
Discussion: The results of this trial will give unique evidence regarding the cost-effectiveness of US as a diagnostic
triage tool in the management of SP in primary care.
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With up to 100 new patient encounters per general
practitioner (GP) per year, and a prevalence of 17-20%
in the general population, shoulder pain (SP) is a com-
mon and sizable problem in primary care [1-4]. About
70% of the patients with a new episode of SP show
incomplete recovery within six weeks, 50% report persis-
tent complaints after six months, and 40% are not
recovered after one year [4]. Troublesome pain is the
most prominent symptom in adult patients with SP
until the age of 65 years [5]. Prolonged and recurrent
pain episodes result in frequent consultations[6]. Within
one year, 40% of the patients with SP have at least one
reconsultation with the GP [4]. Roughly 30% of the
patients with SP report limitations in daily life and sick
leave is common [3]. It is suggested that prolonged and
recurrent episodes generate substantial costs for care
and sick leave [7]. In general, indirect costs, such as
costs caused by sick leave from paid work, are substan-
tial and represent a higher burden to the economy than
direct costs [8]. Hence, there is a great need to improve
diagnosis and prognosis from both the individual patient
perspective as well as from a societal perspective.
Subacromial disorders are considered to be the most
common pathology affecting the shoulder. In 80% of the
cases with SP in primary care, the rotator cuff is the
prominently affected anatomical structure [4]. The spec-
trum of subacromial pathology is extensive and includes
rotator cuff tendinopathy (tendinosis), calcific tendinitis,
partial- or full-thickness tears, and acute or chronic sub-
acromial-subdeltoid bursitis [9-11]. In primary care, the
prevalence of these disorders are unknown. Studies in
secondary care have shown a prevalence ranging from
30-39% for tendinopathy, 13-15% for calcific tendinitis,
13-51% for partial-thickness tears, 24-70% for full-thick-
ness tears, and 12-56% for bursitis [12]. Conflicting the-
ories have been proposed to explain the mechanisms
leading to pathology, and more research is needed to
understand the disease process [10,13,14]. However, the
dominant view is that many shoulder complaints have
their origin in a dynamic pathology, with subacromial
impingement as the initial stage, and rotator cuff tears
as the final stage [15,16].
For all these specific subacromial disorders, specific
therapies are available [9,17]. After the mainstay of para-
cetamol or non-steroidal anti-inflammatory drugs
(NSAIDs), tendinopathy preferably is treated with phy-
siotherapy, calcific tendinitis and bursitis with subacro-
mial corticosteroid injections, partial-thickness tears
with physiotherapy, and in case of full-thickness tears
surgery should be considered. Unfortunately, physical
examinations used to evaluate the various disorders are
fraught with uncertainty [4,10,18]. As a result, the
diagnostic phase does not often lead to a patho-anato-
mical diagnosis. Therefore, the guideline for SP of the
Dutch College of General Practitioners (DCGP) advises
GPs to start treatment based on patients’ signs and
symptoms rather than on a suspected patho-anatomical
diagnosis. The advised treatment for all patients consists
of a stepwise approach, which starts with advice and
paracetamol or NSAIDs for 2 weeks. In persisting cases
subacromial corticosteroid injections and referral to a
physiotherapist are advised, depending on the level of
pain and functional limitations respectively. Referral to a
specialist or imaging modalities are advised if these
usual care treatments fail [4].
The current diagnostic strategy leads to a substantial
case mix, and the stepwise treatment approach is
expected to dilute the effects of the indicated interven-
tions in the total population considerably. This
approach delays specific therapy tailored to the pathol-
ogy, which is remarkable knowing that a more effective
approach to SP is available, which can lead to a better
prognosis and less costs. We hypothesise that the cur-
rent stepwise approach can be improved by giving the
GP more evidence as to the patho-anatomical origin of
the symptoms of SP. Due to the sufficient diagnostic
accuracy [12,19,20] and clear relationship between US
diagnosis and available evidence based therapies, apply-
ing US in the management of SP in primary care can
solve this problem. US has the advantage of being
non-invasive, relatively inexpensive, and producing
high-resolution dynamic images of the shoulder. How-
ever, additional costs of management with US in
patients with SP should be balanced by an increase in
patients’ health status and/or monetary savings for
society. This cost-effectiveness, which has not been
studied before, is the subject of our trial. This study
foresees in the evidence gap that is addressed in the
SP guideline of the DCGP.
Therefore, the primary objective of the present study
is to investigate the effects of diagnostic US and its
related tailored treatment decisions on clinical recovery
and costs (cost-effectiveness) compared to usual care in
individuals with non-chronic SP (pain less than 3
months) in primary care. The secondary objectives of
the study are: (i) to investigate the effects of diagnostic
US and its related treatment decisions on shoulder pain,
performance of daily activities, and health-related quality
of life compared to the usual care; (ii) to determine the
prevalence of the specific subacromial disorders based
on US reports; (iii) to evaluate to what extent the intro-
duction of US influences management decisions, what
type of treatment is provided to what type of patient
(patient characteristics), and the adherence to the initi-
ally applied treatment.
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Design
In a pragmatic design, which initially follows the guide-
line for SP of the DCGP[4], a study consisting of two
phases will be carried out: a Qualification Period of two
weeks followed by a randomised controlled trial (RCT)
with a 50 week follow-up period (Figure 1). The Qualifi-
cation period aims to filter out patients with a favorable
natural course. During the 2-week Qualification period
all patients are advised to start with paracetamol or
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Figure 1 Flowchart of the study
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receive advice regarding activities of daily living, work,
hobbies and sports. This advise fits within the first line
treatment as recommended in the guideline for SP of
the DCGP. Moreover, patients are referred for US of the
shoulder to the radiology department of the Maastricht
University Medical Centre (MUMC) or Orbis Medical
Centre (OMC) in Sittard-Geleen, The Netherlands.
Based on the qualification assessment at 2 weeks,
patients with insufficient improvement qualify for the
RCT. These patients are randomly assigned to the inter-
vention or the control group. The therapies used in
both groups are the same except that therapies used in
the intervention group will be tailored based on the US
results. Primary and secondary outcome measures will
be assessed at baseline, 13, 26, 39 and 52 weeks after
inclusion. Patient recruitment started in November 2010
and patients will be included until October 2012. The
Medical Ethics Committee of the Maastricht University
Medical Centre has approved this protocol (NTR2403).
This trial is officially called the Maastricht Ultrasound
Shoulder pain Trial (MUST).
Setting
Patients for this trial will be recruited and treated by 21
GPs, working in 11 general practices, in the Westelijke
Mijnstreek, a region in the southern part of the Nether-
lands. A total of 80 general practitioners received a let-
ter inviting them to participate in this study. Of them,
21 GPs agreed to participate in the study. They attended
a 2-hour instruction workshop with their practice assis-
tants. This workshop provided information about the
guideline for SP of the DCGP, the inclusion and rando-
misation procedures, as well as the interventions to be
applied. All participating GPs were asked to give the
names of their preferred physiotherapy practices. These
physiotherapists were additionally invited for the work-
shop. In total 26 physiotherapists from 12 of the 14
invited physiotherapy practices attended the workshop.
The physiotherapists were presented with an evidence
based statement regarding subacromial disorders in a
separate 1-hour parallel program [21]. Those two prac-
tices not represented, received a handout of the presen-
tation and study materials.
Study population
The study population will comprise of patients with SP,
who are physically active with troublesome pain, and
visit their GP with an episode of SP. To be eligibly for
recruitment patients have to fulfil the following eligibil-
ity criteria: (i) shoulder pain upon abduction with pain-
ful arc; (ii) symptoms lasting no longer than three
months; (iii) first episode of SP for 12 months; (iv) age
between 18 and 65 years. Exclusion criteria will be: (i)
consultation or treatment for SP in the past three
months; (ii) glenohumeral external rotation range of
motion less than 45 degrees as this is a reason to sus-
pect a glenohumeral disorder like osteoarthritis or a fro-
zen shoulder; (iii) history of fractures of the proximal
humerus or acromion, dislocation and/or surgery of the
affected shoulder; (iv) shoulder complaints caused by
rheumatic disease, suspected referred complaints or
extrinsic cause; (v) history of depressive or anxiety dis-
orders, or pain catastrophising; (vi) inability to complete
a questionnaire independently; (vii) unable to give
informed consent (dementia or psychiatric disorders);
(viii) involved in disability or liability procedures.
Interventions
Before randomisation, US of the shoulder is performed
by a radiologist with 8 to 20 years of experience in mus-
culoskeletal US at the MUMC or OMC using a proto-
col-based scanning approach (Additional file 1) [22-26].
US is an accurate diagnostic instrument to diagnose
subacromial disorders [12]. The distinguishable disor-
ders are tendinopathy, calcific tendinitis, partial and full
thickness tears, and subacromial bursitis.
Intervention group
The advised evidence based, tailored treatment steps are
described in Additional file 2 [4,9,17,27-36]. To prevent
treatment of supposed asymptomatic pathology, GPs will
link US pathology to history and findings from physical
examination. In case pathology other than rotator cuff
disorders is diagnosed, it will be treated according to this
diagnosis (e.g. in cases of signs of rheumatoid arthritis
patients are referred to a rheumatologist). If there is no
detectable pathology, usual care according to the guide-
line for SP of the DCGP will be advised [4]. In cases
where multiple US findings are present, the most relevant
abnormality will be selected by the GP on the basis of the
clinical findings. With an explanation, and within the
recommendations made in the guideline for SP of the
DCGP, GPs are allowed to deviate from the advised treat-
ments steps. The treatments are standardised.
Control group
Usual care according to the guideline for SP of the
DCGP will be applied in the control group. It consists
of a pragmatic, stepwise approach; a wait-and-see policy
with advice and analgesia for another 2 weeks; in per-
sisting cases corticosteroid injections and referral to a
physiotherapist are advised, depending on the level of
pain and functional limitations respectively; referral to a
hospital specialist is advised if conservative treatment
fails [4].
Randomisation and allocation
Based on the qualification assessment at 2 weeks, unrec-
overed patients (measured by the Global Perceived
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are randomly assigned by central block randomisation
(blocks of 4) to the intervention or control group after
stratification for age (≥ 50 years). Neither the patient
nor the GP can be blinded for the allocated treatment.
However, US results are only disclosed to GPs of those
patients in the intervention group, as well as those
patients themselves. In case a patient is allocated to the
intervention group, the GP receives the US result and
the advised corresponding treatment strategy. In the
control group, neither the patients nor the GPs receive
the US results. Their US results will be presented to the
GP at the end of patients’ follow-up period.
The radiologist performing the US, is not allowed to
communicate with the patients about the US findings
and results. In case a fracture, septic bursitis or arthritis,
or a life-threatening disorder (e.g. tumour) is diagnosed,
the radiologist will immediately inform the GP with c.c.
to the investigator, and the patient will be excluded and
not randomised.
Outcome assessment
At baseline, demographic information will be collected
including age, sex and profession, as well as disease spe-
cific information regarding the affected side, onset, dura-
tion of symptoms, possible cause of complaints, history
of shoulder complaints, neck complaints and dominant
arm. A number of outcome measures will be collected
at baseline, 13, 26, 39 and 52 weeks after inclusion
(Table 1).
Primary outcome measure
The primary outcome measure for the clinical effective-
ness is the patient-perceived recovery using the Global
Perceived Effect questionnaire (GPE)[37]; a one-item
score concerning recovery following treatment, mea-
sured on a seven-point ordinal scale. Patients are con-
sidered to be recovered when they report to be much
improved or fully recovered. Together with disease-spe-
cific functional status measures, this is considered to be
an important outcome variable for shoulder complaints.
Secondary outcome measures
Shoulder Pain Score (SPS) T h eS P Si saq u e s t i o n n a i r e
to assess pain experienced by patients with shoulder dis-
orders and includes a 24-hour recall frame. The score
consists of six pain symptom questions and a 10-point
S c a l e[ 3 8 ] .T h eS P Sh a sb e e np r o v e dt ob eau s e f u l
instrument for following the course of the disorder over
time, and gives an indication when a patient feels cured.
Each question receives a maximum of four points. The
VAS is also transposed to a four-point scale (0 = 1, 1-3
=2 ,4 - 6=3 ,7 - 1 0=4 ) .T h em i n i m u mS P Ss c o r ei s
seven points, the maximum score 28.
The Shoulder Disability Questionnaire (SDQ)
The SDQ assesses the performance of daily activities.
This variable will be assessed by a 16-item questionnaire
for functional status limitation in patients with shoulder
disorders and assesses the past 24 hours [39]. The 16
questions can be answered with either yes, no or not
applicable. The final SDQ-score will be calculated by
dividing the number of positive responses by the total
number of applicable items, and multiplying this score
by 100. Consequently, the SDQ-score can range from 0
to 100 with a higher score indicating more severe
disability.
The Euroqol five-item quality of life questionnaire (EQ-5D)
T h eE Q - 5 Di so n eo ft h em o s tc o m m o n l yu s e dg e n -
eric (that is not disease specific) measures used to
quantify the health related quality of life in people
with musculoskeletal disorders [40,41]. It is a patient-
reported measure that consists of two sections. The
first section comprises five questions with three levels
of severity in each (1 = no problem, 2 = moderate
problem, 3 = severe problem) that covers five dimen-
sions of health: mobility, self-care, usual activities,
complaints/discomfort, and anxiety/depression. This
generates 243 theoretically possible health states. Cal-
culation of the index score will be performed accord-
ing to the European recommendations [42]. The
second section is a visual analogue scale ranging from
0 (worst imaginable health state) to 100 (best imagin-
able health state).
Costs
Intervention costs, direct and non-health care costs, as
well as indirect costs will be collected. A questionnaire
c o m p o s e do f2 4q u e s t i o n sr e g a r d i n gr e s o u r c eu s ea n d
expenses in the last three months will be used. In addi-
tion, the research team will contact the GPs, phy-
siotherapists, and hospital specialists in case patients
have been referred, for treatment costs [43]. Standard
unit cost data will be derived from reliable published
sources [44]. The costs related to the intervention itself
Table 1 Outcome measures
Primary outcome T0 T1 T2 T3 T4
Patient-perceived recovery (GPE) ++++
Secondary outcomes
Performance of daily activities (SDQ) +++ +
Shoulder pain (SPS) +++ +
Quality of daily life (EQ-5D) +++ +
Other measures
Costs ++++
Number of re-consultations, corticosteroid
injections, diagnostic imaging procedures, referrals
to physiotherapy and hospital
+
Abbreviations used: T0 - baseline; T1 - 13 weeks; T2 - 26 weeks; T3 - 39 weeks;
T4 - 52 weeks; GPE - Global Perceived Effect; SDQ - Shoulder Disability
Questionnaire; SPS - Shoulder Pain Score; EQ-5D - Euroqol five-item quality of
life questionnaire.
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pricing.
Other assessments
Also in addition, it will be evaluated to what extent
patients are blinded for the US findings and results
prior to randomization, to what extent the introduction
of US influences management decisions, what type of
treatment is provided to what type of patient (patient
characteristics), and what adherence rates to the initial
applied treatment can be shown.
Sample size
T h es a m p l es i z ec a l c u l a t i o ni sb a s e do nar e c o v e r yr a t e
(measured by GPE) of 60% in the control group [4] and
80% in the intervention group after 52 weeks, a two
sided-alpha of 0.05, a statistical power of 0.80, and a
drop-out rate at 52 weeks of 10% [45,46]. We need 90
patients per study group to detect the difference of 20%
between the study groups after 52 weeks; the minimal
clinical important difference. With the expectation that
the Qualification period filters out 20% of the patients,
we need to include 226 patients. With up to 100 new
patient encounters per GP per year [1-4] and approxi-
mately 25 eligible patients per GP per year, two years of
recruitment, 50% consent to the study, and 50% drop-
out for other reasons, we need 20 GPs to participate to
include the required 226 patients. Based on the reported
prevalence, and our experience, we expect to encounter
enough patients with symptomatic US pathology to
complete recruitment within two years.
Data analysis
The primary analysis will be intention-to-treat and will
compare the patient-perceived recovery measured by the
Global Perceived Effect questionnaire (GPE) at 52 weeks
after randomisation of patients managed by US tailored
treatment (intervention group) and those having
received care as usual (control group). In order to study
the influence of protocol violations on the study out-
comes, a per protocol analysis will be performed.
Patients with documented deviations from the study
protocol (that is no adherence to the treatment steps
mentioned in Additional file 2) will be excluded from
this analysis.
Continuous variables will be presented as mean ±
standard deviation and categorical variables as number
(%). The longitudinal trend of primary and secondary
parameters will be compared between the intervention
and control group using logistic and linear mixed mod-
els to take into account the dependency of repeated
measurements and nesting structure of data (patients
within GP practices). Baseline characteristics that a
p r i o r ia r ec o n s i d e r e dt ob ep o s s i b l ep r o g n o s t i cf a c t o r s
(fast or gradual development of SP, possible cause of SP,
dominant shoulder affected, concomitant neck com-
plaints, and physical work with upper extremities), will
be included in the mixed models.
An economic evaluation willb ep e r f o r m e df r o mb o t h
a health care and societal perspective with a time hori-
zon of 52 weeks. The incremental cost-effectiveness
ratios will be expressed as the costs per additionally
recovered patient (from a health care perspective) and
the costs per Quality Adjusted Life Years (from a socie-
tal perspective). Sensitivity analyses will be performed to
assess the influence of relevant factors. Finally, bootstrap
analysis will be performed to quantify the uncertainty
surrounding the incremental costs and effects. Based on
these results, a Cost-Effectiveness Acceptability Curve
will be constructed to show the probability that the
intervention is cost-effective.
Discussion
This study uses a randomised controlled trial design to
investigate whether US as a diagnostic triage tool is
more effective on clinical recovery and is more cost-
effective than continuation of usual care in patients with
non-chronic SP in general practice. This study foresees
in the evidence gap that is addressed in the SP guideline
of the DCGP.
Primary inclusion criterion is the GP’ss u s p i c i o no fa
subacromial disorder being the primary cause of SP.
GPs are daily facing patients with SP and, based on the
guideline for SP of the DCGP, they are able to differ-
entiate between subacromial, glenohumeral and extrinsic
disorders for SP. The pragmatic approach of this trial
leaves them very close to daily practice when consider-
ing recruiting patients for this study.
This study is designed as a randomised controlled
trial. However, since blinding patients is not possible in
this pragmatic study, information bias has to be taken
into account. As a stratagem to prevent this, radiologists
are not allowed to discuss the US findings and results
with patients. To evaluate this information bias, we
included a question in the questionnaire at 13 weeks.
Patients allocated to the control group and their GPs do
not receive the US result until the end of patients’ fol-
low-up period.
The treatment options for the intervention and con-
trol group do not differ significantly. However, the sig-
nificant difference between the treatment regimes in the
intervention and control groups is that patients in the
intervention group receive tailored treatment according
to their patho-anatomical disease state. This in contrast
with patients in the control group, who are treated
according to the guideline SP of the DCGP, and receive
treatment based on complaints. In this cost-effectiveness
study we compare diagnosis - treatment combinations,
and not only treatments. It is our hypothesis that these
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treatment without delay, have a positive effect on
patient recovery and costs. Moreover, the prevention of
unnecessary interventions can contribute to this effect.
In general, the accuracy of US is operator dependent.
In experience hands US is an accurate diagnostic instru-
ment to diagnose subacromial disorders [12]. For study
purposes one can chose for a single operator or multiple
operators per radiology department. For two reasons we
choose for multiple operators. First, due to our design
(the US has to be made within two weeks after patient
inclusion, and the inclusion period runs for two years),
the radiology departments were not able to guarantee a
single operator. Second, a single operator would limit
the external validity, as in The Netherlands it is com-
mon that within a radiology department, more radiolo-
gists are experienced in musculoskeletal ultrasound.
Therefore, all US in our study are only made by experi-
enced radiologists in musculoskeletal ultrasound. For
study purposes, these radiologists use a standardized
protocol (Additional file 1), which was developed by the
project group and radiology departments.
It is likely that degeneration is one of the mechanisms
leading to rotator cuff pathology [14]. As degeneration
is part of the normal aging process, and therefore a
potential confounder, we choose to stratify for age. In
this respect, we realise that degeneration is a continuum,
and evidence for a clear cut-off point for age as a con-
founder is lacking. Although arbitrary, we think it is
plausible to set this cutt-off point for age at 50 years.
Rotator cuff tears are also common in asymptomatic
and unselected populations [47,48]. The incidence of
tears is known to increase with age and can be consid-
ered as part of the normal ageing process [47]. In this
respect, we realise that overdiagnosis is to be avoided.
However, the current diagnostic strategy leads to under-
diagnosis. We do realise that in general a certain per-
centage of US recorded pathology is not directly
responsible for the reported symptoms. Therefore, to
prevent treatment of asymptomatic pathology, US
pathology will be linked to medical history and physical
examination.
As the prevelances of the different subacromial disor-
ders in primary care are unknown, it is questionable
whether we will encounter enough patients to start tai-
lored treatment in the intervention group. Based on the
reported prevalences in secondary care, and our experi-
ences with patients in primary care who underwent
shoulder US, we expect to encounter enough patients
with different symptomatic US pathologies to start tai-
lored treatment.
Physiotherapists generally utilise a variety of techni-
ques such as mobilization, soft tissue massage, exercises
and education. Often, their program is based on their
own experiences. To ensure a consistent program, we
trained the physiotherapists in an evidence based
approach for subacromial disorders (released by the
Royal Dutch Society for Physical Therapy) [21].
This study will ensure that the cost-effectiveness of US
as a diagnostic triage tool in primary care is adequately
evaluated. It will fill the gaps in the current evidence
base and may guide clinical practice and policy. Impor-
tantly, the results obtained can be used to formulate
(new) guidelines. In the Netherlands, guidelines of the
DCGP, including the one for SP, are seen as the “gold
standard” for the management of frequently occurring
diseases and health problems. If US is considered cost-
effective, this pragmatic study will contribute to dissemi-
nation. This potentially reduces unnecessary interven-
tions, reconsultations, and referrals to physiotherapists
and hospital. Referrals will be based on more adequate
questions. If this is a negative trial, then resources will
be saved by not promoting US in the early management
of SP. Overall, quality of care in patients with SP will
improve.
Additional material
Additional file 1: Ultrasound examination technique and diagnosis.
Specification of the US technique and the criteria for diagnosis
Additional file 2: Ultrasound diagnosis tailored treatment steps.
specification of the evidence based tailored treatment steps
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